Loading
A phase 2 trial of Tislelizumab and Cisplatin in oesophageal cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.
SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07700667 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 120 participants planned, started 2026-08-13 and due to reach its primary completion in 2028-12-31. Interventions recorded: SKB500, Tislelizumab, Cisplatin and 5 - FU.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Oesophageal squamous cell carcinoma, Tislelizumab, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Sichuan Kelun-Biotech, Tislelizumab and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tag pipeline.
Shares Tislelizumab, Cisplatin and the tag pipeline.
Shares Sichuan Kelun-Biotech and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/